Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab dose-finding and confirmatory trial in moderate to severe hidradenitis suppurativa
MOH_2023-06-14_012738Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of spesolimab in hidradenitis suppurativa (HS) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-response relationship in phase 2b and Optimal dose selection for phase 3. Started Jun 2023; status: active, not recruiting.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on MOH_2023-06-14_012738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-14_012738.